Should we be worried about hepatitis E?
(Stellenbosch University) Hepatitis E gets little press compared to its better-known cousins A, B and C, but Stellenbosch University virologists say we should wake up to how transmission of this virus is changing.
This study investigated the incidence and timing of significant hepatic events, including HBV reactivation, in patients taking direct-acting antivirals for chronic HCV.Journal of Viral Hepatitis
CONCLUSIONS: We report a high seroprevalence rate and several potential risk factors of HEV infection in a large HIV cohort from Yunnan province in China. Further research on identification of the circulating HEV strains and the clinical outcome of this patient population is required. This article is protected by copyright. All rights reserved
Judge overturns jury award that centered on breakthrough hepatitis C active ingredient sofosbuvir
Authors: Gras G Abstract Communication technologies have invaded our daily lives. Several studies have assessed these technologies in the management of infectious diseases (mainly HIV). Weekly short text messages and real-time compliance monitoring assessed in HIV patients are both associated with higher compliance in low-income countries. Virtual consultations to monitor stable chronic HIV patients or tuberculosis treatment in high-income countries appear to be acceptable and efficient. Although assessed in small studies, virtual monitoring seems to reinforce the doctor-patient relationship and the relation betwee...
Condition: Cirrhosis, Liver Intervention: Other: intestinal microbiota transplant Sponsor: Zhongshan Hospital Xiamen University Recruiting
Yuchen Nan, Chunyan Wu, Qin Zhao, Yani Sun, Yan-Jin Zhang, En-Min Zhou
Abstract The purpose of this study was to compare the efficacy of nucleoside analogues (NAs) in the treatment of HBV-related liver failure. The data of patients with HBV-related liver failure treated with nucleoside analogues were used to conduct a network meta-analysis. A total of 1660 patients from 12 articles about the efficacy of lamivudine, entecavir, telbivudine and tenofovir for HBV-related liver failure treatment were recruited in the study. The highest two- and three-month survival rate was recorded for patients using tenofovir. The end-stage liver disease (MELD) score and mortality in patients undergoing...
ConclusionsIn our early diagnosed cohort, the 9‐year survival with native liver was better than that reported in other studies. Approximately 15% of patients developed liver‐related disease complications, less than previously reported. The long‐term course of SC was negatively influenced by the presence of autoimmune features, but not by concomitant IBD.
Checkpoint inhibition (CPI) with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies became a standard therapy in a variety of tumour entities. In particular, in malignant melanoma, CPI revolutionised the therapy within a few years. None the less, interventions in the immune system with these inhibitors regularly cause immune-related adverse events (irAE). Common irAEs such as colitis, dermatitis, pneumonitis or hepatitis are well known, and recommendations for their diagnosis and management have been outlined [1 –4].
In conclusion, this study found a high prevalence of occult HBV infection among our HIV‐infected population. We also demonstrated that pooled HBV NAT is highly specific, moderately sensitive and cost‐effective. As conventional HBV viral load assays are expensive in resource‐limited settings such as India, pooled HBV DNA NAT might be a good way for detecting occult HBV infection and will reduce HBV‐associated complications.